OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share

Dec 10, 2018 8:30am EST

OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO™ Induces Abscopal Responses In Metastatic Melanoma Patients

Nov 29, 2018 8:00am EST

OncoSec to Present at Piper Jaffray 30th Annual Healthcare Conference

Nov 20, 2018 8:00am EST

OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

Nov 13, 2018 8:00am EST

OncoSec Appoints Robert Ward to its Board of Directors

Nov 08, 2018 8:00am EST

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

Nov 07, 2018 8:00am EST

OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Nov 06, 2018 8:00am EST

OncoSec to Host Conference Call to Review Preliminary KEYNOTE-695 Data

Nov 05, 2018 8:00am EST

OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

Nov 02, 2018 8:00am EDT

OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer

Oct 29, 2018 8:00am EDT